Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 4/20 | 0.53 |
| ▸ | CTSK | P43235 | 3/20 | 0.53 |
| ▸ | CTSL | P07711 | 2/20 | 0.53 |
| ▸ | CTSB | P07858 | 2/20 | 0.53 |
| ▸ | TACR1 | P25103 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4797141 | 1.00 | CTSS (0.53) | CTSSCTSKCTSLCTSBTACR1 | |
| SCHEMBL6161119 | 0.88 | CTSS (0.70) | CTSSCTSKCTSLCTSBATM | |
| SCHEMBL19513108 | 0.88 | CTSS (0.70) | CTSSCTSKCTSLCTSBATM | |
| SCHEMBL18653043 | 0.86 | MMP1 (0.59) | CTSSCTSKCTSLCTSB | |
| SCHEMBL19795766 | 0.86 | MMP1 (0.59) | CTSSCTSKCTSLCTSB | |
| SCHEMBL9248675 | 0.85 | OPRK1 (0.55) | CTSSCTSKALDH1A1THRBCYP2C9 | |
| SCHEMBL24534148 | 0.85 | MME (0.61) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL24534147 | 0.85 | MME (0.61) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL3616167 | 0.84 | MMP1 (0.55) | CTSSCTSKCTSLCTSBALDH1A1 | |
| SCHEMBL3616169 | 0.84 | MMP1 (0.55) | CTSSCTSKCTSLCTSBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE40278-E1 | Heterocyclic amines having central nervous system activity | PHARMACIA & UPJOHN COMPANY (US) | 2008-04-29 | — | — | US | disclosed |
| US-7074927-B2 | Heterocyclic amines having central nervous system activity | PHARMACIA & UPJOHN COMPANY (US) | 2006-07-11 | — | — | US | disclosed |
| US-20050107378-A1 | Heterocyclic amines having central nervous system activity | ROMERO ARTHUR G (US) | 2005-05-19 | — | — | US | disclosed |
| US-RE38452-E1 | SUITABLE FOR TREATING ANXIOLYTIC DISORDER, SCHIZOPHRENIA, PARKINSON'S DISEASE, ANXIETY | PHARMACIA & UPJOHN COMPANY | 2004-03-02 | — | — | US | disclosed |
| US-20020187981-A1 | Heterocyclic amines having central nervous system activity | ROMERO ARTHUR GLENN (US) | 2002-12-12 | — | — | US | disclosed |
| US-20010009916-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | ROMERO ARTHUR G (US) | 2001-07-26 | — | — | US | disclosed |
| EP-1017391-A2 | SUSTAINED RELEASE TABLET FORMULATION TO TREAT PARKINSON DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-12 | — | — | EP | disclosed |
| WO-1999016442-A2 | SUSTAINED RELEASE TABLET FORMULATION TO TREAT PARKINSON DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 1999-04-08 | — | — | WO | disclosed |
| EP-0724584-B1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | UPJOHN CO (US) | 1997-11-05 | — | — | EP | disclosed |
| US-5652245-A | Heterocyclic amines having central nervous system activity | PHARMACIA & UPJOHN COMPANY (US) | 1997-07-29 | — | — | US | disclosed |
| EP-0724584-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 1996-08-07 | — | — | EP | disclosed |
| WO-1995004056-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | THE UPJOHN COMPANY (US) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009916-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | CNR1, CNR2, OPRD1 | CTSS 494/4885CTSK 1319/4885CTSL 1636/4885 |
| US-20020187981-A1 | Heterocyclic amines having central nervous system activity | CNR1, CNR2, OPRD1 | CTSS 488/4885CTSK 1292/4885CTSL 1627/4885 |
| US-20050107378-A1 | Heterocyclic amines having central nervous system activity | CNR1, CNR2, NPY2R | CTSS 447/4885CTSK 1687/4885CTSL 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.